8.61
-0.81(-8.60%)
Currency In USD
| Previous Close | 9.42 |
| Open | 9.09 |
| Day High | 9.5 |
| Day Low | 8.53 |
| 52-Week High | 41.8 |
| 52-Week Low | 5.01 |
| Volume | 10,522 |
| Average Volume | 59,950 |
| Market Cap | 5.06M |
| PE | -0.3 |
| EPS | -29.17 |
| Moving Average 50 Days | 11.37 |
| Moving Average 200 Days | 10.03 |
| Change | -0.81 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.54 as of February 21, 2026 at a share price of $8.61. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $3.76 as of February 21, 2026 at a share price of $8.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
GlobeNewswire Inc.
Jan 27, 2026 1:30 PM GMT
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self-Commercialization of QRX003 in Japan, if App
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
GlobeNewswire Inc.
Jan 20, 2026 1:30 PM GMT
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
GlobeNewswire Inc.
Nov 11, 2025 1:30 PM GMT
Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcy